Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.
PDS Biotechnology Corporation (NASDAQ: PDSB) delivers innovative immunotherapies through its Versamune® platform, targeting cancers and infectious diseases. This news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and corporate developments.
Access primary-source press releases and curated analysis covering PDSB's clinical trials, partnership announcements, and financial disclosures. Track progress across key areas: Phase II/III oncology studies, FDA communications, and strategic collaborations enhancing their nanoparticle-based therapies.
Our repository ensures you stay informed about critical developments in HPV-associated cancer treatments, combination therapy research, and infectious disease vaccine progress. Bookmark this page for direct access to PDSB's verified updates, eliminating the need to scour multiple sources.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the appointment of Dr. Otis Brawley to its Board of Directors. Dr. Brawley, an esteemed oncologist with extensive experience in oncology and pharmaceutical development, is currently the Bloomberg Distinguished Professor at Johns Hopkins University. His past roles include Chief Medical and Scientific Officer at the American Cancer Society and member of the FDA Oncologic Drug Advisory Committee. The company highlights that Dr. Brawley's expertise will be crucial as PDS Biotech advances its clinical programs.
PDS Biotechnology Corporation (Nasdaq: PDSB) has announced its participation in the "Grand Rounds: a Webinar in Biotech and Specialty Pharma" on November 2, 2020, hosted by Alliance Global Partners. This presentation will showcase the company's proprietary Versamune® technology used in cancer therapies and infectious disease vaccines.
The company will also report its third quarter 2020 financial results on November 11, 2020, followed by a conference call on November 12, 2020, at 8:00 am Eastern Time to discuss the results and provide a business update.
PDS Biotech has initiated a Phase 2 clinical trial for PDS0101 combined with standard chemoradiotherapy (CRT) to treat locally advanced cervical cancer. The study, led by MD Anderson Cancer Center, will evaluate the safety and anti-tumor efficacy of this combination in approximately 35 patients. The trial aims to correlate the treatment’s effectiveness with biomarkers of immune response. Dr. Lauren Wood, the Chief Medical Officer, expresses optimism regarding the potential of PDS0101 in enhancing cervical cancer treatments.
PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy firm, announced the virtual presentations of its CEO, Frank Bedu-Addo, at notable investment conferences. The H.C. Wainwright & Co. 22nd Annual Global Investment Conference is set for September 16, 2020, at 2:30 PM ET, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is on September 23, 2020, at 4:10 PM ET. The company specializes in innovative cancer therapies and vaccines, utilizing its proprietary Versamune® technology. A replay of the Oppenheimer presentation will be available for 90 days.
PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company, participated in Noble Capital Markets’ C-Suite Interview Series on August 21, 2020. CEO Frank Bedu-Addo discussed key topics including the status of the PDS0101 oncology candidate, which is undergoing three Phase 2 clinical trials, and the company’s growing portfolio, targeting various cancers and infectious diseases like COVID-19 and the flu. The interview also touched on financial metrics, including current cash position and anticipated value-generating catalysts for the next year.
PDS Biotechnology Corporation (Nasdaq: PDSB) has successfully closed its underwritten public offering of 6,900,000 shares of common stock at a price of $2.75 per share, yielding approximately $19.0 million in gross proceeds. The offering included 900,000 additional shares exercised by the underwriter. Several company insiders participated in the purchase. The shares were offered under a registration statement filed with the SEC. This initiative is aimed at enhancing the company's financial position as it advances its proprietary Versamune® T-cell activating technology for cancer therapies and vaccines.
PDS Biotechnology Corporation (PDSB) announced its Q2 2020 financial results, reporting a net loss of $2.9 million or $0.19 per share, an improvement from a net loss of $3.9 million in Q2 2019. R&D and G&A expenses decreased by 26% and 38%, respectively. The company initiated a Phase 2 trial for PDS0101 to treat HPV-associated cancers and launched new COVID-19 vaccine programs. A collaborative grant was received from NIAID for developing a universal influenza vaccine. PDSB's cash balance stood at approximately $16.9 million as of June 30, 2020.
PDS Biotechnology has announced a public offering of 6,000,000 shares of common stock at $2.75 each, aiming to raise approximately $16.5 million.
The offering, set to close on August 13, 2020, includes an option for underwriters to buy 900,000 additional shares.
Proceeds will fund working capital and general corporate purposes, enhancing its ability to develop cancer therapies and vaccines utilizing its Versamune® technology.
PDS Biotechnology Corporation (PDSB) will announce its second-quarter financial results for the period ending June 30, 2020, on August 13, 2020, before market opening. Following the announcement, executives including Dr. Frank Bedu-Addo will host a conference call to discuss the results and provide a business update at 8:00 am ET. Interested parties can join via phone or through a live webcast on PDS Biotech’s investor relations page. The event will be archived for six months for further access.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced promising preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203). The data show that PDS0203 effectively induces both CD8 killer and CD4 helper T-cells, leading to a 30-45 fold increase in COVID-19 specific T-cells and a 20-25 fold increase in neutralizing antibodies within 14 days. The vaccine demonstrates potential for long-lasting immunity, with effects continuing beyond 30 days. The company also initiated preclinical development for a second candidate, Versamune-CoV-2FC (PDS0204), in partnership with Farmacore Biotechnology.
